LifeMD, Inc. (LFMD) AI Stock Analysis

LifeMD, Inc. operates as a direct-to-patient telehealth company connecting consumers with healthcare professionals across various medical specialties in the United States. Its mobile-first platform provides virtual consultations, prescription medications, diagnostics, and imaging. The company runs specialized platforms including ShapiroMD for hair loss, RexMD for men's health, LifeMD Primary Care, Cleared for allergy and asthma treatments, and Nava MD for dermatology. LifeMD also offers PDFSimpli, a software-as-a-service platform for creating, editing, converting, signing, and sharing PDF documents online. The company was founded in 1994 and rebranded from Conversion Labs, Inc. in February 2021.

Between FY2020 and FY2025, LifeMD generated a five-year revenue compound annual growth rate of 39.1%, expanding from $92.9M in FY2021 to a peak of $212.5M in FY2024. In FY2025, revenue declined 8.7% to $194.1M, gross margin fell to 79.8% from 88.7% in FY2024, and operating margin was -4.0%. Net income improved from -$60.9M in FY2021 to -$7.1M in FY2025, with EPS at $0.00. For the trailing twelve months ended June 30, 2026, revenue was $191.6M with an operating margin of -15.1% and EPS of -$0.51. In the latest quarter ended June 30, 2026, quarterly revenue fell 3.5% year-over-year.

As of June 30, 2026, LifeMD held $25.1M in cash and short-term investments against $6.0M in total debt, resulting in net cash of $19.1M. Shareholders' equity was $8.0M and the current ratio was 0.90. In FY2025, operating cash flow generated $8.3M, while free cash flow was -$1.2M after capital expenditures of $9.5M. The company paid $3.1M in dividends during FY2025, and its share count grew 79.1% over five years.

LifeMD carries a market capitalization of $112.9M and an enterprise value of $128.1M. Its forward P/E of 12.9x is lower than the 17.3x median of its US-listed Healthcare peers, and its price-to-sales multiple of 0.6x sits below the peer median of 4.1x. However, its EV/EBITDA of 36.7x trades at a premium to the peer median of 12.0x. Over the past year, the stock fell 63.6%, lagging the S&P 500 return of 16.8%. Over five years, the stock dropped 54.8% compared to an 83.0% gain for the S&P 500.

Wall Street coverage consists of 8 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell ratings. The mean price target of $8.12 implies an upside of 247.2% from the last close of $2.34. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.17 on revenue of $207.6M. For FY2027, two analysts project EPS of $0.38 and revenue of $245.1M. LifeMD has beaten EPS estimates in 1 of the last 4 quarters, and its next earnings report is scheduled for November 16, 2026.

This page is an AI-written research summary of LifeMD, Inc. (LFMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: LFMD income statement, LFMD balance sheet, LFMD key metrics, LFMD analyst forecast, LFMD chart. See the LFMD stock overview for the latest quote and news.